These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 24054872)

  • 41. Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
    Wang H; Wei X; Zhang D; Li W; Hu Y
    BMC Mol Cell Biol; 2022 Nov; 23(1):51. PubMed ID: 36443669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
    Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
    Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. USP54 is a potential therapeutic target in castration-resistant prostate cancer.
    Zhou C; Zhang X; Ma H; Zhou Y; Meng Y; Chen C; Shi G; Yu W; Zhang J
    BMC Urol; 2024 Feb; 24(1):32. PubMed ID: 38321455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939.
    Pudova E; Kobelyatskaya A; Katunina I; Snezhkina A; Nyushko K; Fedorova M; Pavlov V; Bulavkina E; Dalina A; Tkachev S; Alekseev B; Krasnov G; Volodin V; Kudryavtseva A
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
    Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
    Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation.
    Kim WK; Buckley AJ; Lee DH; Hiroto A; Nenninger CH; Olson AW; Wang J; Li Z; Vikram R; Adzavon YM; Yau TY; Bao Y; Kahn M; Geradts J; Xiao GQ; Sun Z
    Nat Commun; 2024 Feb; 15(1):1231. PubMed ID: 38336745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
    Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
    Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
    Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
    World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.
    Pakula H; Xiang D; Li Z
    Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
    Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.
    Hsieh CL; Botta G; Gao S; Li T; Van Allen EM; Treacy DJ; Cai C; He HH; Sweeney CJ; Brown M; Balk SP; Nelson PS; Garraway LA; Kantoff PW
    Cancer Res; 2015 May; 75(10):1944-8. PubMed ID: 25808865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.
    Akhoundova D; Fischer S; Triscott J; Lehner M; Thienger P; Maletti S; Jacquet M; Lubis DSH; Bubendorf L; Jochum W; Rubin MA
    Diagn Pathol; 2024 Jun; 19(1):83. PubMed ID: 38907236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.